MolCRAFT: Structure-Based Drug Design in Continuous Parameter Space
0
Sign in to get full access
Overview
- This research paper, titled "MolCRAFT: Structure-Based Drug Design in Continuous Parameter Space," explores a novel approach to drug design using generative models in a continuous parameter space.
- The paper addresses the challenges faced by traditional generative models in the context of structure-based drug design (SBDD), such as failure modes and limitations in exploring the chemical space.
- The proposed MolCRAFT model aims to overcome these challenges by leveraging a Bayesian flow network architecture to generate drug-like molecules in a continuous parameter space.
Plain English Explanation
The paper focuses on a problem in the field of drug discovery, where researchers face difficulties in using machine learning models to design new drug molecules. Traditional generative models, which are used to create new molecule designs, often struggle to explore the vast chemical space effectively and can produce molecules that are not suitable for further development as potential drugs.
The researchers behind this study have developed a new approach called MolCRAFT, which uses a type of machine learning model called a Bayesian flow network. This model allows them to generate drug-like molecules in a continuous parameter space, rather than the discrete space used by many other generative models. This continuous approach is designed to help the model explore the chemical space more efficiently and generate molecules that are more promising for further drug development.
Technical Explanation
The paper introduces MolCRAFT, a structure-based drug design (SBDD) framework that utilizes a Bayesian flow network to generate drug-like molecules in a continuous parameter space. This approach aims to address the limitations of traditional generative models in SBDD, such as their inability to effectively explore the vast chemical space and their tendency to generate molecules that are not suitable for further development.
The Bayesian flow network architecture used in MolCRAFT allows for the generation of molecules in a continuous parameter space, rather than the discrete space typically used by other generative models. This continuous approach is designed to enable more efficient exploration of the chemical space and the generation of molecules that are more likely to be suitable for further drug development.
The paper presents experiments that demonstrate the performance of MolCRAFT in generating drug-like molecules and its ability to outperform traditional generative models in terms of various metrics, such as drug-likeness and synthetic accessibility.
Critical Analysis
The paper acknowledges the limitations of traditional generative models in SBDD and proposes a promising solution in the form of MolCRAFT. The use of a Bayesian flow network architecture to generate molecules in a continuous parameter space is a novel and potentially impactful approach.
However, the paper does not provide a comprehensive comparison of MolCRAFT to other state-of-the-art methods in the field, such as AutoDiff, LatentChemSpace, or StructLDM. Additionally, the paper does not address potential challenges in the practical implementation and deployment of MolCRAFT in real-world drug discovery pipelines.
Further research could explore the integration of MolCRAFT with other modalities, such as protein-molecule binding information, as explored in MolBind, or the use of diffusion models, as discussed in Diffusion-Schrodinger, to further enhance the performance and applicability of the framework.
Conclusion
The MolCRAFT framework represents a promising approach to structure-based drug design, leveraging a Bayesian flow network to generate drug-like molecules in a continuous parameter space. This approach aims to address the limitations of traditional generative models in effectively exploring the vast chemical space and producing molecules suitable for further drug development.
The continuous parameter space approach used by MolCRAFT is a novel and potentially impactful contribution to the field of computational drug discovery. Further research and comparative analysis with other state-of-the-art methods could help solidify the advantages and practical applications of this framework.
This summary was produced with help from an AI and may contain inaccuracies - check out the links to read the original source documents!
Related Papers
0
MolCRAFT: Structure-Based Drug Design in Continuous Parameter Space
Yanru Qu, Keyue Qiu, Yuxuan Song, Jingjing Gong, Jiawei Han, Mingyue Zheng, Hao Zhou, Wei-Ying Ma
Generative models for structure-based drug design (SBDD) have shown promising results in recent years. Existing works mainly focus on how to generate molecules with higher binding affinity, ignoring the feasibility prerequisites for generated 3D poses and resulting in false positives. We conduct thorough studies on key factors of ill-conformational problems when applying autoregressive methods and diffusion to SBDD, including mode collapse and hybrid continuous-discrete space. In this paper, we introduce MolCRAFT, the first SBDD model that operates in the continuous parameter space, together with a novel noise reduced sampling strategy. Empirical results show that our model consistently achieves superior performance in binding affinity with more stable 3D structure, demonstrating our ability to accurately model interatomic interactions. To our best knowledge, MolCRAFT is the first to achieve reference-level Vina Scores (-6.59 kcal/mol) with comparable molecular size, outperforming other strong baselines by a wide margin (-0.84 kcal/mol). Code is available at https://github.com/AlgoMole/MolCRAFT.
Read more5/29/2024
0
AUTODIFF: Autoregressive Diffusion Modeling for Structure-based Drug Design
Xinze Li, Penglei Wang, Tianfan Fu, Wenhao Gao, Chengtao Li, Leilei Shi, Junhong Liu
Structure-based drug design (SBDD), which aims to generate molecules that can bind tightly to the target protein, is an essential problem in drug discovery, and previous approaches have achieved initial success. However, most existing methods still suffer from invalid local structure or unrealistic conformation issues, which are mainly due to the poor leaning of bond angles or torsional angles. To alleviate these problems, we propose AUTODIFF, a diffusion-based fragment-wise autoregressive generation model. Specifically, we design a novel molecule assembly strategy named conformal motif that preserves the conformation of local structures of molecules first, then we encode the interaction of the protein-ligand complex with an SE(3)-equivariant convolutional network and generate molecules motif-by-motif with diffusion modeling. In addition, we also improve the evaluation framework of SBDD by constraining the molecular weights of the generated molecules in the same range, together with some new metrics, which make the evaluation more fair and practical. Extensive experiments on CrossDocked2020 demonstrate that our approach outperforms the existing models in generating realistic molecules with valid structures and conformations while maintaining high binding affinity.
Read more4/4/2024
0
Structure-based Drug Design Benchmark: Do 3D Methods Really Dominate?
Kangyu Zheng, Yingzhou Lu, Zaixi Zhang, Zhongwei Wan, Yao Ma, Marinka Zitnik, Tianfan Fu
Currently, the field of structure-based drug design is dominated by three main types of algorithms: search-based algorithms, deep generative models, and reinforcement learning. While existing works have typically focused on comparing models within a single algorithmic category, cross-algorithm comparisons remain scarce. In this paper, to fill the gap, we establish a benchmark to evaluate the performance of sixteen models across these different algorithmic foundations by assessing the pharmaceutical properties of the generated molecules and their docking affinities with specified target proteins. We highlight the unique advantages of each algorithmic approach and offer recommendations for the design of future SBDD models. We emphasize that 1D/2D ligand-centric drug design methods can be used in SBDD by treating the docking function as a black-box oracle, which is typically neglected. The empirical results show that 1D/2D methods achieve competitive performance compared with 3D-based methods that use the 3D structure of the target protein explicitly. Also, AutoGrow4, a 2D molecular graph-based genetic algorithm, dominates SBDD in terms of optimization ability. The relevant code is available in https://github.com/zkysfls/2024-sbdd-benchmark.
Read more6/6/2024
0
Structure-based drug design by denoising voxel grids
Pedro O. Pinheiro, Arian Jamasb, Omar Mahmood, Vishnu Sresht, Saeed Saremi
We present VoxBind, a new score-based generative model for 3D molecules conditioned on protein structures. Our approach represents molecules as 3D atomic density grids and leverages a 3D voxel-denoising network for learning and generation. We extend the neural empirical Bayes formalism (Saremi & Hyvarinen, 2019) to the conditional setting and generate structure-conditioned molecules with a two-step procedure: (i) sample noisy molecules from the Gaussian-smoothed conditional distribution with underdamped Langevin MCMC using the learned score function and (ii) estimate clean molecules from the noisy samples with single-step denoising. Compared to the current state of the art, our model is simpler to train, significantly faster to sample from, and achieves better results on extensive in silico benchmarks -- the generated molecules are more diverse, exhibit fewer steric clashes, and bind with higher affinity to protein pockets.
Read more5/8/2024